<SEC-DOCUMENT>0001558370-19-007085.txt : 20190805
<SEC-HEADER>0001558370-19-007085.hdr.sgml : 20190805
<ACCEPTANCE-DATETIME>20190805163023
ACCESSION NUMBER:		0001558370-19-007085
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190802
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190805
DATE AS OF CHANGE:		20190805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36177
		FILM NUMBER:		19999045

	BUSINESS ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		240-243-1201

	MAIL ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8-k.htm
<DESCRIPTION>8-K
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.3.0.107-->
<!--Created on: 8/5/2019 2:30:13 PM-->
<html>
	<head>
		<title>
			glyc_Current Folio 8k
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;border-top:3pt double #000000 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-weight:bold;font-family:Times New Roman,Times,serif;font-size: 14pt;">
			<font style="display:inline;">UNITED STATES</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 14pt;">
			<font style="display:inline;font-weight:bold;font-size:14pt;">SECURITIES AND EXCHANGE COMMISSION</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-weight:bold;">Washington, DC 20549</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1.2pt;color:black;background-color:black;" align="center"></hr></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 14pt;">
			<font style="display:inline;font-weight:bold;font-size:14pt;">FORM 8&#8209;K</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">CURRENT REPORT</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">Pursuant to Section 13 or 15(d) of</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">The Securities Exchange Act of 1934</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">Date of Report (Date of earliest event reported): August 2, 2019</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1.2pt;color:black;background-color:black;" align="center"></hr></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 14pt;">
			<font style="display:inline;font-weight:bold;font-size:14pt;">GlycoMimetics, Inc.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">(Exact name of registrant as specified in its charter)</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:29.44%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.74%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:31.78%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:32.54%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:29.44%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;text-decoration:underline;">Delaware</font></p>
				</td>
				<td valign="bottom" style="width:03.74%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:31.78%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;text-decoration:underline;">001-36177</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:32.54%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;text-decoration:underline;">06-1686563</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:29.44%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">(State or other jurisdiction of&nbsp;incorporation)</font></p>
				</td>
				<td valign="bottom" style="width:03.74%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:31.78%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">(Commission File Number)</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:32.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">(IRS Employer<br />Identification No.)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">9708 Medical Center Drive</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">Rockville, MD 20850</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">(Address of principal executive offices, including zip code)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">(240) 243-1201</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">(Registrant&#x2019;s telephone number, including area code)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">N/A</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">(Former name or former address, if changed since last report)</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font>
		</p>
		<p style="margin:5pt 0pt 5pt 14.25pt;text-indent: -14.25pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">[&nbsp;&nbsp;] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font>
		</p>
		<p style="margin:5pt 0pt 5pt 14.25pt;text-indent: -14.25pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">[&nbsp;&nbsp;] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font>
		</p>
		<p style="margin:5pt 0pt 5pt 14.25pt;text-indent: -14.25pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">[&nbsp;&nbsp;] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font>
		</p>
		<p style="margin:0pt 0pt 0pt 14.25pt;text-indent: -14.25pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">[&nbsp;&nbsp;] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font>
		</p>
		<p style="margin:0pt 0pt 0pt 14.25pt;text-indent: -14.25pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">Securities registered pursuant to Section 12(b) of the Act:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;">
			<tr>
				<td valign="top" style="width:161.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:108.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:215.05pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:161.60pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;text-decoration:underline;">Title of each class</font></p>
				</td>
				<td valign="top" style="width:108.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:5pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;text-decoration:underline;">Trading Symbol(s)</font></p>
				</td>
				<td valign="top" style="width:215.05pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:5pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;text-decoration:underline;">Name of each exchange on which registered</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:161.60pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:5pt 0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Common Stock, $0.001 par value</font></p>
				</td>
				<td valign="top" style="width:108.15pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:5pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">GLYC</font></p>
				</td>
				<td valign="top" style="width:215.05pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:5pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">The Nasdaq Stock Market</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">Ind&#xED;cate by&nbsp;check&nbsp;mark&nbsp;whether&nbsp;the&nbsp;registrant&nbsp;is&nbsp;an&nbsp;emerging&nbsp;growth Company as defined in Rule 405 of the Securities Act of 1933 (&#xA7;230.405 of this&nbsp;chapter) or Rule 12b&#8209;2 of the Securities Exchange Act of 1934 (&#xA7;240.12b&#8209;2 of this&nbsp;chapter).</font>
		</p>
		<p style="margin:0pt 0pt 0pt 14.25pt;text-indent: -14.25pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">Emerging&nbsp;Growth Company &#x2611;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">If&nbsp;an&nbsp;emerging&nbsp;growth&nbsp;company, &nbsp;indicate&nbsp;by&nbsp;check&nbsp;mark&nbsp;if&nbsp;the&nbsp;registrant has elected&nbsp;not to use the extended transition&nbsp;period&nbsp;for&nbsp;complying&nbsp;with&nbsp;any new or revised&nbsp;financial&nbsp;accounting&nbsp;standards&nbsp;provided&nbsp;pursuant to Section 13(a) of the Exchange Act. &nbsp;&#x2611;</font>
		</p>
		<p style="margin:0pt;border-bottom:3pt double #000000 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Item 8.01&nbsp;&nbsp;Other Events.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">On August 2, 2019, GlycoMimetics, Inc. (the &#x201C;</font><font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">Company</font><font style="display:inline;font-size:10pt;">&#x201D;) issued a press release in connection with Pfizer&#x2019;s announcement of top-line results from a Phase 3 clinical trial evaluating the Company&#x2019;s product candidate rivipansel in patients with sickle cell disease.&nbsp;A copy of this press release is furnished herewith as Exhibit&nbsp;99.1 to this Current Report and is incorporated herein by reference.</font><font style="display:inline;color:#000000;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">Item 9.01 Exhibits.</font><font style="display:inline;font-weight:bold;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">(d)&nbsp;Exhibits</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:40.00pt;padding:0pt 0.7pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.20pt;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:343.15pt;padding:0pt 0.7pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:40.00pt;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Exhibit</font></p>
				</td>
				<td valign="top" style="width:06.20pt;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:343.15pt;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:40.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Number</font></p>
				</td>
				<td valign="top" style="width:06.20pt;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:343.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Exhibit&nbsp;Description</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:40.00pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0.7pt 0pt 0pt;height:14.75pt">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">99.1</font></p>
				</td>
				<td valign="top" style="width:06.20pt;height:14.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:343.15pt;padding:0pt 0.7pt 0pt 0pt;height:14.75pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="ex-99d1.htm"><font style="display:inline;font-size:10pt;">Press Release dated August 2, 2019, &#x201C;GlycoMimetics Reports Top-line Results From Pfizer&#x2019;s Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease.&#x201D;</font></a> &nbsp; &nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-weight:bold;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">SIGNATURES</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:37.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:58.92%;padding:0pt;">
					<p style="margin:0pt;font-weight:bold;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:41.08%;padding:0pt;">
					<p style="margin:0pt;font-weight:bold;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">GLYCOMIMETICS, INC.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:58.92%;padding:0pt;">
					<p style="margin:0pt;font-weight:bold;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:41.08%;padding:0pt;">
					<p style="margin:0pt;font-weight:bold;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:55.56%;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:03.36%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:41.08%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">/s/ Brian M. Hahn</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:58.92%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Date:&nbsp; August 5, 2019</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:41.08%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Brian M. Hahn</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:58.92%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:41.08%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Chief Financial Officer and Senior Vice President</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex-99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.3.0.107-->
<!--Created on: 8/5/2019 2:30:12 PM-->
<html>
	<head>
		<title>
			glyc_Ex99_1
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt 0pt 12pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;">Exhibit 99.1</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;"><img src="ex-99d1g001.jpg" style="width: 3.76in; height: 0.82in" alt="Picture 1"></font>
		</p>
		<p style="margin:0pt;line-height:100%;border-bottom:1pt none #D9D9D9 ;text-align:center;font-family:Courier New;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 41.75pt;line-height:100%;text-indent:30.25pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:center;font-family:Courier New;font-weight:bold;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 41.75pt;line-height:100%;text-indent:30.25pt;border-top:1pt none #D9D9D9 ;text-align:center;font-family:Courier New;font-weight:bold;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">GLYCOMIMETICS REPORTS TOP-LINE RESULTS FROM PFIZER&#x2019;S PHASE 3 CLINICAL TRIAL EVALUATING RIVIPANSEL IN SICKLE CELL DISEASE</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:150%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:5pt 0pt;line-height:150%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="text-transform:uppercase;display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">ROCKVILLE, MD, aUGUST 2, 2019</font><font style="text-transform:uppercase;display:inline;font-family:Calibri;font-size:11pt;"> &#x2013; </font><font style="display:inline;font-family:Calibri;font-size:11pt;">GlycoMimetics, Inc. (Nasdaq: GLYC) reported that Pfizer Inc. (NYSE: PFE) announced today that the Phase 3 </font><font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;text-decoration:underline;">R</font><font style="display:inline;font-family:Calibri;font-size:11pt;">ivipansel (GMI-1070): </font><font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;text-decoration:underline;">E</font><font style="display:inline;font-family:Calibri;font-size:11pt;">valuating </font><font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;text-decoration:underline;">S</font><font style="display:inline;font-family:Calibri;font-size:11pt;">afety, </font><font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;text-decoration:underline;">E</font><font style="display:inline;font-family:Calibri;font-size:11pt;">fficacy and </font><font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;text-decoration:underline;">T</font><font style="display:inline;font-family:Calibri;font-size:11pt;">ime to Discharge (RESET) pivotal study did not meet its primary or key secondary efficacy endpoints. The objective of the trial was to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell disease (SCD) who were hospitalized for a vaso-occlusive crisis (VOC) and required treatment with intravenous (IV) opioids. The primary endpoint was time to readiness-for-discharge and the key secondary efficacy endpoints were time-to-discharge, cumulative IV opioid consumption, and time to discontinuation of IV opioids.</font>
		</p>
		<p style="margin:0pt;line-height:150%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&#x201C;We are both surprised and deeply disappointed by this outcome, as we had strongly hoped that rivipansel would have a positive benefit for people living with sickle cell disease,&#x201D; said Rachel King, Chief Executive Officer of GlycoMimetics.&nbsp;&nbsp;&#x201C;We are grateful to the many people who supported and advanced this program over the years of clinical study, especially to sickle cell patients and their families.&#x201D;</font>
		</p>
		<p style="margin:5pt 0pt;background-color: #FFFFFF;line-height:150%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">About Rivipansel</font>
		</p>
		<p style="margin:5pt 0pt;line-height:150%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Rivipansel is a glycomimetic drug candidate that acts as a pan-selectin antagonist, meaning it binds to all three members of the selectin family &#x2013; E-,&nbsp;P- and L-selectin. Rivipansel is an investigational treatment for VOC in people with SCD and not approved for use. <a name="_Hlk14642806"></a>In 2011, GlycoMimetics and Pfizer Inc. entered into a worldwide license agreement for the development and, if approved by applicable regulatory authorities, commercialization of rivipansel.&nbsp;Since completion of the Phase 2 clinical trial, Pfizer has been responsible for clinical development of rivipansel, including the RESET clinical trial.&nbsp;</font>
		</p>
		<p style="margin:12pt 0pt;line-height:150%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:12pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">About SCD and VOC</font>
		</p>
		<p style="margin:12pt 0pt;line-height:150%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<a name="_Hlk14642738"></a><font style="display:inline;font-family:Calibri;font-size:11pt;">SCD is the most common inherited blood disorder in the United States, impacting approximately 100,000 people. Worldwide, approximately 100 million people carry the SCD trait and an estimated five million live with the disease. While the majority of people with SCD are of African descent, the disease can affect all ethnic groups, especially those from areas where malaria is or was endemic, such as the Middle East, India and the Southern Mediterranean. <a name="_Hlk13734572"></a>Acute pain crises or VOCs are the most common clinical manifestation of SCD. A VOC occurs when sickled red blood cells irritate the lining of blood vessels and cause an inflammatory response leading to vascular occlusion, tissue ischemia and pain.&nbsp; </font>
		</p>
		<p style="margin:12pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">About GlycoMimetics, Inc. </font>
		</p>
		<p style="margin:12pt 0pt;line-height:150%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">GlycoMimetics&nbsp;is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role.&nbsp;&nbsp;GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is an investigational treatment for VOC being evaluated by Pfizer. GlycoMimetics'&nbsp;wholly owned drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML.&nbsp;&nbsp;It has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and is being evaluated across a range of patient populations including a company-sponsored Phase 3 trial in relapsed/refractory AML.&nbsp; GlycoMimetics&nbsp;has also completed a Phase 1 clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist.&nbsp;GlycoMimetics&nbsp;is located in&nbsp;Rockville, MD&nbsp;in the&nbsp;BioHealth Capital Region. Learn more at&nbsp;</font><font style="display:inline;font-family:Calibri;">www.glycomimetics.com</font><font style="display:inline;font-family:Calibri;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;line-height:150%;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;color:#000000;font-size:11pt;">Forward-Looking Statements</font>
		</p>
		<p style="margin:0pt 0pt 21pt;background-color: #FFFFFF;line-height:150%;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;color:#000000;font-size:11pt;">This press release contains forward-looking statements regarding the clinical development and potential benefits and impact of the Company&#x2019;s drug candidates. These forward-looking statements include those relating to the planned clinical development of the Company&#x2019;s wholly owned product candidates and the expected timing for receiving and reporting data from Pfizer&#x2019;s Phase 3 clinical trial of rivipansel. Actual results may differ materially from those in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing GlycoMimetics, please see the risk factors described in the Company&#x2019;s annual report on Form 10-K filed with the&nbsp;U.S. Securities and Exchange Commission&nbsp;(SEC) on&nbsp;March 6, 2019, and other filings&nbsp;GlycoMimetics&nbsp;makes with the&nbsp;SEC&nbsp;from time to time. Forward-looking statements speak only as of the date of this release, and&nbsp;GlycoMimetics&nbsp;undertakes no obligation to update or revise these statements, except as may be required by law.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:12pt 0pt;line-height:150%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;"># # #</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Source: GlycoMimetics</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">Investor Contact:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Shari Annes</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Phone: 650-888-0902</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Email: sannes@annesassociates.com</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">Media Contact:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Jamie Lacey-Moreira</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Phone: 410-299-3310</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Email: jamielacey@presscommpr.com</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:150%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex-99d1g001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d1g001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M)Y_B'P'?6UF.7N+6<3;!ZD 8'XD5V^@>(M+\3Z8NH:3=+/ 3ANS(W]UAU!H
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M$/AVQUBWP(KJ$2$9^X>C*3[$$?A7$_!4!O!5Z" 0=3G!!^BUQVI:E?\ @?\
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MEM>?&LGLS_\ H-'B_P#UUK_NM_2G%1YXPY5JA2<^253F>C([F\U];<:@S>5
M<$*H& #TX_QK:MM95M"_M"9<,@(91W;../KQ1K('_".S<<>6O\Q6+%$\O@V3
M8"2DI<@>@/-9I1J03:MK8T;G3FTG?2Y)#/K^JJUQ;R+%%GY0, 'Z>M7-)UBZ
M-\VG:BN)QPK8P<]<'''3O6+I^GZ;=VVZ?4/(E&=R-@?EGK5_2M.TU]01[:_>
M22%MVTIC=BM*D86::_#]3.G*I>+3W\_T,V8:G_;B"1A]NR-I^7TX]NE:DMY>
M1Z_8PRLF\K&)/W:DY/WN<>N>E,N_^1TB_P!Y/Y4:C_R.%M_O1]*;:E:Z^R))
MQO9OXBYK.MS070L;%=TYQEL9P3T 'K5-G\2VJ^<^YUSRN%;]!S^51W$@TWQ:
M;BY4^6S;@V.Q&,_A_2MV;7M-ABW_ &E7Y^ZG)K-KD45&-[HU3YW)SG:S(=0U
M2YL]$2Y:#RKB0A-I.0I.>?TK-T^XUZ26"8.)X93SDC '?..E;%_=Z=-I/FW#
MA[:7A=O4GV]Q7+RL-'NXIM.OA-&_.T'G'HPHHQ4HM<NOH%:3C)/FT\F=U14$
MUW!;+&;B18O,.U=Q[U/UKCLSMNCSCXH?\A[P)_V'8?\ T):A\<^+?$NC_$/1
M]&T(1SB]M3MM9$78TA9@'9L;@% R0".E3?%#_D/>!/\ L.P_^A+3=: /Q\\-
MD@'&F3$>W$E(9%J^D_$+0M)GUZ/Q?'?W-K&9Y[![-5A=%Y95/7@9[ GVKI'\
M<V$'P[C\77"%87MEE\D-R9#QY8/^]QG\:V]; .@:B",@VLO_ *":\?N;*YNO
MV=='GMHO.^PRK=R18^^BROG\!G)]@: .FL=+^(7BBVCU.^\2)X?CF DAL+6T
M61D4\C>S$'/3(Y_#I6IX<?QOIGB#^R=>\G5M.>,O%JL*+$R$?PNGO[9/N><=
M+HFM6'B'28-3TV=9K:9<@@\J>ZD=B.XJ-O$>D+XACT$WT9U1XS*+<9)"CGGL
M#CG!YQ0!J454.J:>NI+IIOK87[)O%J9E\TKZ[<YQ[XJW0!XM\1M1C\._&?PY
MK]_#.-.ALPCRI&2-VZ8$#L2-P)'7%::PLT-QJNCS1ZSH]Q<37/FV8)F@,CM(
MRO'U."QZ?-ZKWKTV^L+/4[.2TOK:*YMY!AXI4#*?P->4ZM\*-4\.W[ZS\/M3
MEM)QRUC+)\KC^Z&/!'L^?K5TZDH.\2*E.-2/+(M6]S#=0B6WE22,\;E.1D=1
M]:EKFK?QEIFI:FUEXLLY?"_B,$*U]$A$4I[>:A['U.>.C+6_="\TE$?4DC:T
M< QZC;'?;R#L2>J9]^/1C7HTL5&>DM&>95PDX:QU1-02 ,G@"H$GDN[K['IM
MO)?77&8X<;8P>[L>%'?GD]@:R]>UKP]X9;9KMRNN:L#A=(LF_P!'C;TD/\1_
MWO;Y!UJJN(A#3=DTL-.IKLC5M?M>K*[:9'']F3_6:A<-LMT ZD'^/'^SQZD5
MR7B35M-UKQ/X'T'P_/+JC:/.%FN(HCL<%HLE<9X 0DGH/6M>#PMXV^);QS^)
M+AM$T$8,=A"NUBO;Y/ZM^ KU+PYX3T7PI9_9M(L4AR ))3\TDG^\QY/TZ>@K
MSJM651ZGITJ,:2M$VJY7Q'\.O#7B>Y^UWUD8[WC_ $JV<QR'ZD<'ZD&NJHK(
MU//(?@UX;\Y'OKO5]21&W+%>7FY ?^ @']:[VTM+:PM(K2T@C@MXEVQQ1J%5
M1Z "IJ* ,GP]X<T_POI\ECIJR+#),T["1]QW-C//X"N*TU$\8?&"]U;:K:?X
M=C^QP-C[]P<[C[[?F'_?)KTNFI&D8(C15!.2%&,F@!U<?J_PS\.ZMJK:HJW6
MGWSG,D]A.86<^IQQGWQFNPHH Y7P]\//#WAR^.H6UO+<7Y&/M=Y*99!]">!]
M0,UK:]X=TGQ-IQL=7LTN8<Y7/#(?56'(/TK4HH X"#X.^%HYHFN&U&]AB.4M
M[JZ+1+Z<#%=K<:?;W%DMFR;(% "I'\H '0#T%6J*:;3NA-)JS(;6UBL[5+>(
M'RUS@$YZG-5K+2+33YGEMU8,PVG)SQ5^BGSRUUW%R1TTV*-UI-K>7<=S*&\V
M,#!5L=#D4HTJV&I?;P'\_.<[N.F.GTJ[11SRM:XO9QO>Q232K:/46OE#><Q)
M//'(QTHO]*MM29#<!SL! VMCK5VBCGE>]P]G&UK:$-Q:QW-HUM)GRV !P>:;
M9V4-C;>1"#Y>2?F.>M6**7,[6*Y5>_4R)_#6G32%PCQYZB-L"KECIMKIZD6\
M>&/5SRQ_&K=%4ZDVK-D*E!.Z6I2?2K:345OF#><I!'/' QTHETJVFOTO7#><
MA!&#QQ5VBESR[C]G'L5KRPMK^(1W$88 Y!Z$?0UGQ^&-.1PQ$K@?PL_'Z5LT
M4XU)Q5DPE2A)W:*UQ86UU:BVEA4Q#[H'&WZ>E4K?PYI]M.LH1W93D!VR :UJ
M*%4DE9,'3@W=HQ[[39M0UBW:8+]CA7.,_>;TQ^7Y5L444I2<DEV'&"BVUU,G
M6?#FGZ]<Z;<7RR&33KE;JWV/MPZD$9]1Q1<>'-/N?$]IXAD63[?:0M!$0_R[
M3G.1_P "-:U%241W$"75M+;R9\N5"C8/8C!JGHNBV>@Z+;Z39*PM(%*HLC;C
M@DDY/?J:T** .&NOA/X:EO);JR-_I;2Y,B:?=&)&S_L\@?08%;'AKP3H/A,2
M-I=GMN)1B2YE8O*_?ECV]A@5T-% '.OX*T=_&L?BPI-_::1[ ?,^3[I3.WUV
MDCTKHJ** "BBB@#&\1>%=%\567V75[&.=1]R3I)&?56'(_EZUY9/X1\;?#62
M2X\+73:UH9),NGS+N8+W^3O]4P3W&*]LHH \)LKOQK\0+;^S_#FEP^%?#Y.)
M9(E\L,3][! !;OPH'H37H7A#X8Z!X1"3Q0_;-1')O+@ L#_LCHOX<^]=I10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
E110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
